Literature DB >> 8555482

Internalization of bound fibrinogen modulates platelet aggregation.

J D Wencel-Drake1, C Boudignon-Proudhon, M G Dieter, A B Criss, L V Parise.   

Abstract

In agonist-stimulated platelets, the integrin alpha IIb beta 3 (glycoprotein IIb-IIIa) is converted from an inactive to an active fibrinogen receptor, thereby mediating platelet aggregation. With time after agonist addition, at least two events occur: fibrinogen becomes irreversibly bound to the platelet and, when stirring is delayed, platelets lose the ability to aggregate despite the presence of maximally bound fibrinogen. Because we previously identified an actively internalized pool of alpha IIb, beta 3 in platelets, we explored the possibility that both of these events might result from the internalization of fibrinogen bound to active alpha IIb beta 3. Under conditions of irreversible fibrinogen binding, fluorescence microscopy showed that biotinylated fibrinogen is rapidly internalized by activated platelets to a surface-inaccessible, intracellular pool. Flow cytometric analysis showed that the observed loss in accessibility to extracellular probes immediately precedes a loss in ability to the platelets to aggregate. Moreover, prevention of irreversible fibrinogen binding results in a prevention of internalization and a retention of aggregation capacity. Thus, the internalization of fibrinogen from the activated platelet surface appears to contribute not only to the irreversible phase of fibrinogen binding, but also to the downregulation of platelet adhesiveness. Fibrinogen internalization is therefore likely to represent a fundamental regulatory mechanism that modulates platelet function.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8555482

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  Clustering induces a lateral redistribution of alpha 2 beta 1 integrin from membrane rafts to caveolae and subsequent protein kinase C-dependent internalization.

Authors:  Paula Upla; Varpu Marjomäki; Pasi Kankaanpää; Johanna Ivaska; Timo Hyypiä; F Gisou Van Der Goot; Jyrki Heino
Journal:  Mol Biol Cell       Date:  2003-12-02       Impact factor: 4.138

2.  Platelet Toll-Like-Receptor-2 and -4 Mediate Different Immune-Related Responses to Bacterial Ligands.

Authors:  Marius Niklaus; Philipp Klingler; Katja Weber; Angela Koessler; Sabine Kuhn; Markus Boeck; Anna Kobsar; Juergen Koessler
Journal:  TH Open       Date:  2022-07-11

3.  Arf6 controls platelet spreading and clot retraction via integrin αIIbβ3 trafficking.

Authors:  Yunjie Huang; Smita Joshi; Binggang Xiang; Yasunori Kanaho; Zhenyu Li; Beth A Bouchard; Carole L Moncman; Sidney W Whiteheart
Journal:  Blood       Date:  2016-01-06       Impact factor: 22.113

4.  Platelet hyperreactivity explains the bleeding abnormality and macrothrombocytopenia in a murine model of sitosterolemia.

Authors:  Taisuke Kanaji; Sachiko Kanaji; Robert R Montgomery; Shailendra B Patel; Peter J Newman
Journal:  Blood       Date:  2013-08-07       Impact factor: 22.113

5.  Quantitative detection of platelet GPIIb-IIIa receptor antagonist activity using a flow cytometric method.

Authors:  L J Green; P Marder; S L Um; J A Jakubowski; J B Lawrence
Journal:  J Clin Lab Anal       Date:  1998       Impact factor: 2.352

6.  Sulfatides partition disabled-2 in response to platelet activation.

Authors:  Karen E Drahos; John D Welsh; Carla V Finkielstein; Daniel G S Capelluto
Journal:  PLoS One       Date:  2009-11-24       Impact factor: 3.240

7.  Cytoskeletal perturbation leads to platelet dysfunction and thrombocytopenia in variant forms of Glanzmann thrombasthenia.

Authors:  Loredana Bury; Emanuela Falcinelli; Davide Chiasserini; Timothy A Springer; Joseph E Italiano; Paolo Gresele
Journal:  Haematologica       Date:  2015-10-09       Impact factor: 9.941

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.